Get the Stockscreener App
22.00
0.34%
-0.03
Jasper Therapeutics Inc stock is traded at $22.00, with a volume of 76,038.
It is down -0.34% in the last 24 hours and up +36.54% over the past month.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
See More
Previous Close:
$22.03
Open:
$21.98
24h Volume:
76,038
Relative Volume:
0.33
Market Cap:
$332.77M
Revenue:
-
Net Income/Loss:
$-64.47M
P/E Ratio:
-22.22
EPS:
-0.99
Net Cash Flow:
$-52.33M
1W Performance:
-1.77%
1M Performance:
+36.54%
6M Performance:
-10.46%
1Y Performance:
+209.14%
1-Day Range:
$21.80
$22.29
1-Week Range:
$20.92
$23.04
52-Week Range:
$4.00
$31.01
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
(650) 549-1400
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-23 | Initiated | CapitalOne | Overweight |
| Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Credit Suisse | Outperform |
| Oct-21-21 | Initiated | William Blair | Outperform |
| Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire
JSPRJasper Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Long Term Trading Analysis for (JSPR) - Stock Traders Daily
Jasper Therapeutics' SWOT analysis: briquilimab stock shows promise amid challenges - Investing.com
Jasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from HC Wainwright - MarketBeat
Jasper Therapeutics to Present Preclinical Briquilimab Data - GlobeNewswire
Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - StockTitan
Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria - GlobeNewswire
Molina Healthcare (MOH) Set to Announce Earnings on Wednesday - Defense World
Analysts Set Rush Street Interactive, Inc. (NYSE:RSI) Target Price at $11.17 - Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $74.86 Consensus Target Price from Brokerages - MarketBeat
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline
Jasper Therapeutics (NASDAQ:JSPR) Rating Reiterated by HC Wainwright - Defense World
Metagenomi (NASDAQ:MGX) Stock Rating Reaffirmed by HC Wainwright - Defense World
JMP Securities Reiterates Market Outperform Rating for Jasper Therapeutics (NASDAQ:JSPR) - Defense World
JMP Securities analysts initates a Mkt outperform rating for Jasper Therapeutics Inc (JSPR) - Knox Daily
Analysts review Ares Capital Corp’s rating - Knox Daily
Jasper Therapeutics shares keep buy rating with positive study results By Investing.com - Investing.com Canada
DoubleVerify Holdings Inc [DV] stock was sold by Allais Nicola T at the price of US$30365.0 - Knox Daily
When (JSPR) Moves Investors should Listen - Stock Traders Daily
Jasper Therapeutics Inc (JSPR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Jasper gains 11% on data for briquilimab in urticaria (NASDAQ:JSPR) - Seeking Alpha
Jasper Therapeutics shares hold as Oppenheimer maintains $80 target By Investing.com - Investing.com Canada
Jasper Therapeutics shares hold as BTIG maintains $90 target By Investing.com - Investing.com UK
You Should Read This Analysis Before Investing in Jasper Therapeutics Inc (NASDAQ:JSPR) - US Post News
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday? - Yahoo Finance
Jasper reports promising early results in urticaria study - Investing.com
Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday? - Benzinga
Jasper Therapeutics Stock Gains on Strong Briquilimab Trial Results - MarketWatch
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - GlobeNewswire
Jasper reports promising early results in urticaria study By Investing.com - Investing.com UK
American Century Companies Inc. Has $320,000 Stock Holdings in Arcos Dorados Holdings Inc. (NYSE:ARCO) - Defense World
American Century Companies Inc. Grows Position in Hippo Holdings Inc. (NYSE:HIPO) - Defense World
Novavax (NASDAQ:NVAX) versus Jasper Therapeutics (NASDAQ:JSPR) Critical Contrast - Defense World
Jasper Therapeutics' SWOT analysis: briquilimab's potential in mast cell diseases - Investing.com India
Oppenheimer maintains Outperform rating on Jasper Therapeutics shares By Investing.com - Investing.com Canada
8,750 Shares in Sunrun Inc. (NASDAQ:RUN) Bought by Point72 Asia Singapore Pte. Ltd. - Defense World
Susquehanna Fundamental Investments LLC Invests $23.60 Million in Light & Wonder, Inc. (NASDAQ:LNW) - Defense World
1832 Asset Management L.P. Buys 1,538 Shares of Vanguard Total Stock Market ETF (NYSEARCA:VTI) - Defense World
Fanconi Anemia Market Expected to Experience Major Growth - openPR
Fanconi Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novartis, Foresee Pharma, Rocket Pharma, Jasper Therapeutics - The Globe and Mail
Jasper Therapeutics (NASDAQ:JSPR) Rating Reiterated by JMP Securities - MarketBeat
Benjamin F. Edwards & Company Inc. Decreases Stock Holdings in Hartford Schroders Tax-Aware Bond ETF (NYSEARCA:HTAB) - Defense World
Jasper Therapeutics Inc [JSPR] Shares Jump Approximately 156.76% Over the Year - Knox Daily
Insider Selling: Kabot Brian, Momentus Inc [MNTS] Director divested 400 shares - Knox Daily
Jasper Therapeutics Inc (JSPR) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Jasper Therapeutics Inc’s Market Journey: Closing Weak at 18.23, Down -16.34 - The Dwinnex
Jasper concerns driven by Celldex data ‘overdone,’ says Stifel - TipRanks
Front Street Capital Management Inc. Sells 4,073 Shares of Kimball Electronics, Inc. (NASDAQ:KE) - Defense World
First Light Asset Management LLC Sells 482 Shares of Simulations Plus, Inc. (NASDAQ:SLP) - Defense World
Booz Allen Hamilton Holding Co. (NYSE:BAH) Shares Acquired by Providence Capital Advisors LLC - Defense World
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):